摘要
目的观察埃克替尼联合恩度对表皮生长因子受体(EGFR)突变阳性肺腺癌患者的临床效果及预后的影响。方法回顾性选取124例晚期EGFR突变阳性肺腺癌患者为研究对象,根据治疗方案分为埃克替尼组(单用埃克替尼)及恩度联合组(埃克替尼联合恩度)。比较两组患者治疗前和治疗4周期时肿瘤标记物和免疫功能指标水平;比较两组近期疗效;观察两组治疗期间不良反应发生情况;采用Kaplan-Meier法比较两组患者远期疗效无进展生存时间(PFS)及总生存时间(OS)生存曲线。结果治疗4周期时,两组患者肿瘤指标及CD8^(+)水平均较治疗前明显降低(P<0.05),且恩度联合组低于埃克替尼组(P<0.05);两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均较治疗前升高(P<0.05),且恩度联合组高于埃克替尼组(P<0.05)。恩度联合组OS长于埃克替尼组(P<0.05)。两组患者近期疗效、PFS、不良反应比较,差异均无显著性(P>0.05)。结论埃克替尼联合恩度的二线治疗方案有助于提高EGFR突变阳性肺腺癌患者的总生存期,且安全性良好。
Aim To observe the clinical efficacy and prognosis of Ectinib combined with Endu in the treatment of epidermal growth factor receptor(EGFR)mutation-positive lung adenocarcinoma.Methods 124 patients with advanced EGFR-mutation-positive lung adenocarcinoma were retrospectively selected as the study subjects,and were divided into Ectinib group(Ectinib alone)and Endu combined group(Ectinib combined with Endu)according to the treatment plan of the patients.The levels of tumor markers and immune function indexes were compared between the two groups before treatment and after 4 cycles of treatment.The short-term curative effects of the two groups were evaluated.The occurrence of adverse reactions during treatment was observed in the two groups.Kaplan-Meier method was used to compare long-term curative effects of the survival curves of progression-free survival(PFS)and o verall survival(OS)between the two groups.Results After 4 cycles of treatment,the levels of tumor indexes and CD8^(+)in two groups were significantly lower than them before treatment(P<0.05),and Endu combined group was lower than Ectinib group(P<0.05).The levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in both groups were higher than them before treatment(P<0.05),and Endu combined group was higher than Ectinib group(P<0.05).The OS of the Endu combination group was longer than that of the Ecetinib group(P<0.05).There was no significant difference in recent efficacy,PFS,and adverse reactions between the two groups of patients(P>0.05).Conclusion The second-line treatment regimen of Ecetinib combined with Endu can help improve the o verall survival of EGFR mutation positive lung adenocarcinoma patients and is safe.
作者
卢春霞
邢燕飞
崔宝生
陈坤燕
LU Chunxia;XING Yanfei;CUI Baosheng;CHEN Kunyan(Department of Respiratory and Critical Care Medicine,Qidong People's Hospital,Qidong Liver Cancer Institute,Affiliated Qidong Hospital of Nantong University,Nantong 226200,Jiangsu,China;Department of Medical Oncology,Qidong People's Hospital,Qidong Liver Cancer Institute,Affiliated Qidong Hospital of Nantong University,Nantong 226200,Jiangsu,China;Department of Thoracic Surgery,Qidong People's Hospital,Qidong Liver Cancer Institute,Affiliated Qidong Hospital of Nantong University,Nantong 226200,Jiangsu,China)
出处
《中南医学科学杂志》
CAS
2024年第3期449-452,共4页
Medical Science Journal of Central South China
基金
南通市卫生健康科研基金(QNZ2022086)。
作者简介
卢春霞,硕士,副主任医师,研究方向为肺部恶性肿瘤的诊治,E-mail:108411335@qq.com;通信作者:陈坤燕,副主任医师,研究方向为肿瘤疾病的诊治,E-mail:ztf111@126.com。
